EAST HANOVER, N.J., Aug. 4 /PRNewswire/ -- The US Food and Drug Administration (FDA) has approved two single-pill combination medications, Diovan HCT(R) (valsartan and hydrochlorothiazide) and Exforge ...
Patients undergoing HCT are prone to developing acute kidney injury (AKI). AKI itself adversely affects short- and long-term outcome of those patients. In fact, in patients receiving HCT short- and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback